|
|
Profile
|
Delegates :
Yoshiyuki Sakuraba |
|
Incorporated :
February 20 , 2017 |
Paid in Capital :
100 Million yen |
Employees :
10 人 |
Address :
Dai 2 Fujikoshi Building. 6F Shinagawa-ku, Higashi-gotanda 5-23-1 TOKYO
〒141-0022
|
TEL/FAX :
03-5422-6501 / 03-5422-6502 |
URL：
www.varinos.com |
Attachment :
 Varinos株式会社案内_v10.pdf [ 1.4MiB ] |
Mission/Background :
Varinos Inc is a biotechnology company startuped on 20th February 2017, aim to develop a next generation clinical genomic testing. Our goal is to change the genomic test to the thing everyone has in common and feel familiar. For first step, we focused to innovate reproductive health by endometrial flora test using the next-generation sequencer(NGS). |
|
Technology & Business
|
The Endometrial Flora Test is an infertile screening test based on endometrial and vaginal microbiota. In December 2016, Spanish research team reported that an amount of good bacteria, lactobacillus, existed in the endometrium were different between the non-pregnant group and the live birth group. In May 2018, our collaborators also reported that Japanese pregnant women's endometrial were also dominated with lactobacillus. For further research, more than 50 clinics use our test to understand cause of infertility and improve the pregnancy success rate. Microbiome analysis using NGS has been conducted at Varinos Shinagawa laboratory which is a registered clinical testing laboratory.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
Endometrial Flora Test
|
Service/Marketing
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Highlights
|
We just published a paper describing a endometrial microbiota in Japanese population (Kyono et al. Reprod Med Biol. 2018).
|
|
|